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Introduction {#sec1}
============

Drugs often have multiple targets in vivo that can lead to unintended side effects. Identifying unintended drug targets and their in vivo relevance is a fundamental challenge in chemical biology. 5-Nitrofurans are a class of drugs that save thousands of lives as front-line treatments for parasitic trypanosome infections in Latin America and Africa, and they are also effective antibiotics in human and veterinary medicine ([@bib3]; [@bib7]; [@bib26]; [@bib29]). 5-Nitrofurans are of such importance to human health that the World Heath Organization deems the 5-nitrofuran, nifurtimox, an essential medicine and Bayer HealthCare provides nifurtimox free of charge for trypanosome infections. 5-Nitrofurans are prodrugs, and their relative specificity comes from parasitic and bacteria-specific nitroreductases (NTRs) that reduce the 5-NO~2~ functional group to a toxic anion radical, thereby generating reactive oxygen species and inducing cell death. Despite their widespread use, 5-nitrofurans have serious toxic side effects ([@bib3]). For nifurtimox, toxic side effects lead to treatment cessation in over 30% of patients with Chagas disease, which is caused by *Trypanosoma cruzi* infection ([@bib3]). Clinical side effects are complex and can vary between populations, but they include polyneuropathy, depression, forgetfulness, alcohol intolerance, and headaches, as well as gastrointestinal complications. There is currently no treatment strategy available to reduce the off-target toxic side effects of 5-nitrofurans.

Over decades of research, scientists have identified multiple human enzymes capable of 5-nitrofuran reduction in vitro, in cells or tissues ([@bib11]; [@bib31]; [@bib30]). However, the question of whether these enzymes are relevant to 5-nitrofuran side-effect activity and the potential for therapeutic intervention to inhibit their off-target activity in vivo is unanswered. Drug mechanism of action is readily examined in the zebrafish model system, in which clinically active compounds can be directly assayed in the transparent embryo ([@bib43]). Within 2 to 5 days of development in zebrafish, most tissues and organs have formed, thereby enabling the identification of tissue-specific drug activities and/or bioactivation. These features allow facile phenotypic chemical screens within the whole animal. Phenotypic small-molecule screens in zebrafish have enabled the identification of new biological pathways, novel bioactive chemicals, and unexpected potential for known drugs ([@bib37]). Drugs often have multiple targets in vivo, and examining the effects of small molecules on the developing zebrafish can also identify unintended drug targets ([@bib13]; [@bib14]; [@bib18]; [@bib32]).

Here, we use a multispecies approach to identify ALDH2 as a mediator of 5-nitrofuran toxicity in yeast and zebrafish, and we show that 5-nitrofurans are substrates for human ALDH2 in vitro. In a zebrafish phenotypic screen, we found that 5-nitrofurans are melanocytotoxic. We exploited this highly visible in vivo activity to generate a 5-nitrofuran probe, identify ALDH2 as a 5-nitrofuran target, and validate the interaction in vivo. This interaction is conserved from yeast to human, and is also relevant for the clinically active 5-nitrofuran nifurtimox. We propose that this new interaction may be relevant to some of the 5-nitrofuran toxicity observed in the clinic.

Results {#sec2}
=======

5-Nitrofurans Are Active in Zebrafish {#sec2.1}
-------------------------------------

Melanocytes are pigment-producing cells that generate black melanin, and pigmented melanocytes are clearly visible in the developing zebrafish beginning at 28 hr postfertilization (hpf; [Figure 1](#fig1){ref-type="fig"}A). We identified four 5-nitrofuran compounds, NFN1 (Maybridge BTB05727), NFN2 (SEW00138), NFN3 (BTB13657), and NFN4 (BR00087), in a chemical screen for modulators of melanocyte development in zebrafish embryos ([Figures 1](#fig1){ref-type="fig"}A and 1C; see Methods). We also found that zebrafish were sensitive to the clinically active 5-nitrofuran nifurtimox ([Figures 1](#fig1){ref-type="fig"}B and 1C). 5-Nitrofuran treatment directly affected the melanocyte and melanocyte progenitor viability in a dose-dependent manner and was independent of tyrosinase activity ([Figure S1](#app2){ref-type="sec"} available online; [Movie S1](#mmc2){ref-type="supplementary-material"}). Thus, 5-nitrofurans are melanocytotoxic in zebrafish, and unlike prodrugs that are bioactivated by pigmentation enzymes ([@bib15]; [@bib40]), their activity is independent of tyrosinase. Altered pigmentation is not a feature of 5-nitrofuran toxicity in humans, but melanocyte specificity in zebrafish provided a rapid, convenient, and highly visible assay to study 5-nitrofuran activity in an animal model, independent of trypanosome infection.

5-Nitrofuran Activity Requires the 5-NO~2~ Moiety {#sec2.2}
-------------------------------------------------

5-Nitrofurans are prodrugs, and the 5-NO~2~ moiety is essential for bioactivation in parasites and bacteria ([@bib23]). We modified NFN1 by replacing the NO~2~ moiety with a hydrogen atom ([Figure 1](#fig1){ref-type="fig"}C, NFN1.1; [Table 1](#tbl1){ref-type="table"}; [Supplemental Information](#app2){ref-type="sec"}). In contrast to treatment with NFN1, NFN1.1 had no effect on zebrafish melanocytes, and the melanocyte remained pigmented and intact ([Figure 1](#fig1){ref-type="fig"}A; [Table 1](#tbl1){ref-type="table"}). Nitrofuran activity in melanocytes is therefore dependent upon the 5-NO~2~ functional group. As in humans, zebrafish do not have NTRs (which are present in trypanosomes) to process the 5-NO~2~ functional group, and thus, the effects of NFN1 on zebrafish melanocytes may provide information about alternative methods of 5-nitrofuran processing.

Nitrofurans Bind ALDH2 in Zebrafish {#sec2.3}
-----------------------------------

To identify the possible targets of the 5-nitrofurans, we performed affinity purification to capture 5-nitrofuran interacting proteins in zebrafish extracts. First, we generated a series of 5-nitrofuran derivatives and tested their activity in zebrafish ([Table 1](#tbl1){ref-type="table"}; [Supplemental Information](#app2){ref-type="sec"}). Importantly, 5-nitrofuran derivatives containing a phenyl ring (NFN5, NFN5.1, NFN5.2) effectively targeted zebrafish melanocytes ([Table 1](#tbl1){ref-type="table"}). As substitution at the *para* position of the phenyl ring in NFN5.1 and NFN5.2 was tolerated, a 5-nitrofuran probe was generated by linking to biotin through the *para* position of the phenyl ring (Pr-NFN; [Figure 2](#fig2){ref-type="fig"}A). Next, the 5-nitrofuran probe was bound to streptavidin beads, and protein complexes captured from zebrafish extract derived from 3-day embryos were subjected to tandem mass spectrometry. A 57-kD binding protein was identified as aldehyde dehydrogenase (Aldh) 2b ([Figure 2](#fig2){ref-type="fig"}B; [Table S1](#app2){ref-type="sec"}). Zebrafish have two *aldh2* ([@bib19]; [@bib36]) genes (*a* and *b*) that are orthologs of human ALDH2 ([Figure S2](#app2){ref-type="sec"}); *aldh2b* is expressed in neural crest derived cells, including presumptive melanocytes ([@bib38]). To confirm the identity of the 57-kD protein, we repeated our affinity purification protocol and performed western blotting with anti-Aldh2 zebrafish antibodies raised against both a and b forms of Aldh2 ([@bib19]) ([Figure 2](#fig2){ref-type="fig"}C). As a control, we generated a furan probe that was identical to the nitrofuran probe except that it lacked the 5-NO~2~ functional group (Pr-FN; [Figure 2](#fig2){ref-type="fig"}A). Aldh2 (either a or b) bound more strongly to the 5-nitrofuran probe than to the control probe, and not to streptavidin beads alone ([Figure 2](#fig2){ref-type="fig"}C). These experiments validate Aldh2 as a 5-nitrofuran binding protein.

Aldh2 Is Required for 5-Nitrofuran Activity in Zebrafish {#sec2.4}
--------------------------------------------------------

Aldh2 catabolizes toxic aldehydes in the liver after alcohol consumption ([@bib10]), in the heart after ischemia ([@bib4]), and in dopamine metabolism ([@bib42]). We asked if 5-nitrofuran toxicity was dependent on Aldh2 in zebrafish. The natural product daidzin, found in the Kudzu vine (*Pueraria lobata*), is a potent and specific inhibitor of human ALDH2 and has long been used in traditional medicines as an antidipsotropic ([@bib16], [@bib17]; [@bib21]). More recently, ALDH2 inhibitors have been shown to reduce anxiety associated with treatment of cocaine and alcohol addiction ([@bib1]; [@bib42]). We reasoned that ALDH2 inhibitors were likely to prevent the toxicity of 5-nitrofurans in zebrafish because (1) human ALDH2 is closely related to zebrafish Aldh2 (a and b forms) ([Figure S2](#app2){ref-type="sec"}), and (2) computational modeling of zebrafish Aldh2b bound to daidzin suggests that critical drug-protein interactions are conserved between species ([Figure 3](#fig3){ref-type="fig"}A). Treatment of zebrafish embryos with daidzin protected melanocytes from the cytotoxicity of the coadministered 5-nitrofuran NFN1 ([Figure 3](#fig3){ref-type="fig"}B), as well as the clinically active 5-nitrofuran nifurtimox ([Figure 3](#fig3){ref-type="fig"}C). Thus, coadministration of the Aldh2 inhibitor daidzin abrogates the activity of NFN1 and nifurtimox in zebrafish.

To provide additional evidence that the action of daidzin was by inhibition of Aldh2 and not an additional unintended target, zebrafish embryos were cotreated with NFN1 and a second ALDH1/2 inhibitor, disulfiram (DSF). DSF, also called Antabuse and Antabus, is used to treat chronic alcoholism by preventing the ALDH2-dependent metabolism of alcohol and producing enhanced sensitivity to alcohol. DSF also chelates copper, and we and others have found that DSF prevents pigmentation of zebrafish melanocytes prior to melaninization, most likely due to inhibition of copper-dependent pigmentation enzymes ([Figure S3](#app2){ref-type="sec"}; [@bib27]). DSF treatment of embryos 3 days postfertilization (dpf) that had fully pigmented melanocytes had no effect on melanocyte integrity, while DSF prevented melanocyte toxicity upon cotreatment with NFN1 ([Figure 3](#fig3){ref-type="fig"}B). Taken together, these experiments with two chemically independent ALDH2 inhibitors support a biological role for Aldh2 in the bioactivation of 5-nitrofuran melanocytotoxicity in zebrafish.

*ALDH2* is regulated in a tissue-specific manner, and in particular, εPKC can directly modulate ALDH2 during ischemic preconditioning in the heart ([@bib4], [@bib5]). We identified the PKC inhibitors PKC412 and Ro318220 as chemical suppressors of 5-nitrofuran activity in zebrafish by screening a library of 80 known kinase inhibitors. Treatment of 3 dpf zebrafish embryos with PKC412 or Ro318220 had no effect on melanocyte viability ([Figure 3](#fig3){ref-type="fig"}B). However, treatment with PKC412 or Ro318220 prevented NFN1 activity in melanocytes ([Figure 3](#fig3){ref-type="fig"}B). We tested a third PKC inhibitor, GF109203X, that can inhibit ethanol or dopamine D2 receptor agonist NPA-induced intracellular translocation of εPKC ([@bib41]). GFX109203X had no effect on melanocytes alone, but we found that it could also suppress NFN1 melanocytotoxicity ([Figure S3](#app2){ref-type="sec"}). GFX109203X was also effective at preventing the activity of nifurtimox in zebrafish melanocytes ([Figure 3](#fig3){ref-type="fig"}C). Although we do not know if PKC directly enhances Aldh2b activity or expression in zebrafish, these results suggest that PKC activity is important for 5-nitrofuran cytotoxicity within the melanocyte.

ALDH2 Contributes to Background Adaptation in Zebrafish Melanocytes {#sec2.5}
-------------------------------------------------------------------

We wanted to understand why zebrafish melanocytes were sensitive to 5-nitrofuran treatment, when this is not a feature of 5-nitrofuran toxicity in patients. Unlike human melanocytes, zebrafish melanocytes respond to environmental conditions by concentrating or dispersing their melanosomes in light or dark conditions, respectively ([@bib20]). This effect is termed background adaptation and is a dopaminergic response ([@bib20]). A role of Aldh2 in zebrafish background adaptation has not been previously identified, but *aldh2b* is specifically expressed in developing pigment cells ([@bib38]), and ALDH2 is required for dopamine metabolism in mammals ([@bib5]). We tested the effects of ALDH2 inhibition on background adapation in zebrafish and found that daidzin treatment blocked dispersal of melanin in zebrafish melanocytes in the dark ([Figure 3](#fig3){ref-type="fig"}D). These observations suggest that Aldh2 activity is required for regulation of zebrafish background adaptation, and they may explain the sensitivity of zebrafish melanocytes to 5-nitrofurans.

Multispecies Conservation of the 5-Nitrofuran-ALDH Interaction {#sec2.6}
--------------------------------------------------------------

Chemical-genetic and chemical-chemical interactions identified in yeast are often conserved in multicellular species including zebrafish and mammals ([@bib13]). Budding yeast have five ALDH genes (*ALD2--6*) that all share 42%--48% similarity with human *ALDH 1/2* ([Figure S2](#app2){ref-type="sec"}). Yeast also have two fungal-specific nitroreductase-like proteins, but these share little similarity with the nitroreductases that are known to reduce nitrofurans ([@bib9]). To establish that 5-nitrofurans also showed activity in yeast, liquid cultures were treated with increasing concentrations of NFN1 ([Figure 4](#fig4){ref-type="fig"}A). Yeast were highly sensitive to NFN1, which inhibited growth even at submicromolar concentrations. In contrast, treatment with the control furan compound, NFN1.1, had no effect on yeast growth, even at 100 μM. These data indicate that the toxicity of 5-nitrofurans in yeast is dependent on the 5-NO~2~ moiety. To test whether NFN1 toxicity was dependent on ALDH activity, we tested drug combinations in yeast cultures. Increasing concentrations of daidzin rescued the effects of 50 μM NFN1 on the yeast growth rate in a dose-dependent fashion, whereas daidzin alone had no effect on growth ([Figure 4](#fig4){ref-type="fig"}B).

Mutations that render yeast resistant to a specific compound can provide direct links to the target pathway ([@bib13]). We determined whether yeast strains bearing deletions in each of the *ALD* genes (orthologs of human and zebrafish *ALDH1/2*) were resistant to 5-nitrofuran treatment. The *ald2*Δ, *ald3*Δ, *ald4*Δ, and *ald5*Δ deletion strains each exhibited the same sensitivity to NFN1 as wild-type (data not shown). In contrast, an *ald6*Δ strain was significantly less sensitive to NFN1 treatment, as was an *ald2*Δ*ald3*Δ double-deletion strain ([Figures 4](#fig4){ref-type="fig"}C and 4D). These effects of different *ald* mutations appeared to be additive, as a triple *ald2*Δ*ald3*Δ*ald6*Δ deletion strain was almost completely resistant to 50 μM NFN1 treatment ([Figure 4](#fig4){ref-type="fig"}D). Once activated, 5-nitrofurans cause DNA damage, and consistent with this observation, we find that chemical-genetic profiles in yeast indicate that disruption of DNA damage repair pathways causes hypersensitivity to 5-nitrofurans ([Figure S4](#app2){ref-type="sec"}).

To further validate the genetic dependence of 5-nitrofuran bioactivity on Aldh2, we used morpholino oligonucleotides (MOs) to knockdown *aldh2b* in zebrafish. Single-cell embryos were injected with a splice-site-blocking *aldh2b* MO and at 2 dpf were treated with NFN1. PCR analysis of the splice-site MO indicated that *aldh2b* morphants had reduced levels of correctly spliced *aldh2b* transcript in addition to a misspliced transcript, indicating that the *aldh2b* morphants are hypomorphic for *aldh2b* ([Figure S4](#app2){ref-type="sec"}). We consistently found that the splice-site-blocking *aldh2b* MO conferred partial resistance to a low treatment dose (0.8 μM) of NFN1 melanocytotoxicity ([Figure 4](#fig4){ref-type="fig"}E). An *aldh2b*-translation-block MO also conferred partial resistance to a short NFN1 treatment ([Figure S4](#app2){ref-type="sec"}). We conclude that there is a genetic dependence on Aldh2b for 5-nitrofuran activation in zebrafish, in line with genetic studies in yeast.

5-Nitrofurans Are Substrates for Human ALDH2 {#sec2.7}
--------------------------------------------

There are 19 ALDH enzymes in humans, each with specific targets and additional activities ([@bib22]). To determine whether the 5-nitrofuran-ALDH2 interaction is conserved in humans we asked whether human ALDH2 could bind 5-nitrofurans directly. Purified human ALDH2 was added to the 5-nitrofuran probe (Pr-NFN), a furan control probe (Pr-FN), or streptavidin beads alone. In an analogous manner to the experiments using zebrafish extracts, human ALDH2 binding was strongly enriched in association with the 5-nitrofuran, while the control furan and the streptavidin beads alone did not bind ALDH2 ([Figure 5](#fig5){ref-type="fig"}A).

Given our results with daidzin in yeast and zebrafish, we proposed that NFN1 was probably a substrate of ALDH enzymes. ALDH2 enzymes have reducing potential as well as dehydrogenase activity ([@bib6]; [@bib22]), and it has been shown that in the absence of a reducing agent, ALDH2 inactivates itself during the bioactivation of substrates such as nitroglycerine (GTN) ([@bib5]; [@bib39]). Consistent with this, we found that in the absence of a reducing agent, NFN1, but not the no-nitro NFN1.1, inactivated recombinant human ALDH2 in vitro ([Figures 5](#fig5){ref-type="fig"}B--5D). Likewise, we found that ALDH2 activity was reduced by 39.6%, 77.6%, and 96.5% following 10 min incubation with 5 μM nifurtimox, 16.7 μM nifurtimox, and 50 μM nifurtimox, respectively ([Figure 5](#fig5){ref-type="fig"}C). Importantly, as with the zebrafish studies, these experiments were performed with nifurtimox at concentrations that are within the range of those recorded in the serum of nifurtimox-treated patients ([@bib28]; [@bib33]). For both NFN1- and nifurtimox-inactivated ALDH2, the subsequent addition of a reducing agent (TCEP) led to partial reactivation of the enzyme, in line with literature studies using the accepted substrate, GTN ([Figure 5](#fig5){ref-type="fig"}D). We observe that the NFN1-ALDH2 interaction is stronger than the nifurtimox-ALDH2 in zebrafish and in our biochemical assay. This raises the possibility that the mechanism of action of nifurtimox is more complex than that of NFN1, or that NFN1 may in fact be a more effective 5-nitrofuran substrate of ALDH2 than nifurtimox.

Daidzin Does Not Affect Nifurtimox Trypanocidal Activity {#sec2.8}
--------------------------------------------------------

In an attempt to develop a clinically testable hypothesis, we examined the genome sequence of the trypanosomatids to identify possible ALDH enzymes in *T. brucei*, *T. cruzi* and *Leishmania* ([Figure S2](#app2){ref-type="sec"}) ([@bib2]; [@bib8]; [@bib21]; [@bib22]; [@bib34]). Given the absence of an obvious ALDH2 in *Trypanosoma* we hypothesized that while Aldh2 inhibition would protect the zebrafish melanocytes and yeast cells from 5-nitrofuran activity, ALDH2 inhibitors might not protect trypanosomes from 5-nitrofuran sensitivity ([Figure 6](#fig6){ref-type="fig"}A). We grew the bloodstream-form *T. brucei* (strain 427) in HMI9 media and determined the trypanocidal activity of nifurtimox in the absence and presence of daidzin. Trypanosomes were stained with an Alamar Blue vital dye as an indicator of *Trypanosoma* survival. We found that nifurtimox was equally effective in the absence (ED~50~ = 2.12 ± 0.17 μM; slope 1.00) and presence (ED~50~ = 2.18 ± 0.10 μM; slope 0.98) of daidzin ([Figure 6](#fig6){ref-type="fig"}B). The trypanocidal effect of nifurtimox against bloodstream *T. brucei* obtained in these assays was comparable to previously observed effects ([@bib29]; [@bib35]). Daidzin treatment alone showed no trypanocidal effect up to 100 μM (data not shown). We conclude that daidzin does not interfere with 5-nitrofuran trypanocidal activity, consistent with a lack of an *ALDH2* in trypanosomes.

Discussion {#sec3}
==========

We have used a multispecies, chemical-biology approach to identify 5-nitrofurans as substrates for ALDH2. We have identified a series of 5-nitrofuran compounds by phenotypic screening in zebrafish and have shown that 5-nitrofuran-specific melanocytotoxicity in vivo is mediated at least in part by Aldh2 ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Zebrafish gene products are usually conserved in humans and are often sensitive to clinically active drugs at physiological concentrations ([@bib43]). As shown here, phenotypic chemical screens in zebrafish are effective because (1) the rapid and cell-type-specific toxicity of 5-nitrofurans can be visualized in real time ([Movie S1](#mmc2){ref-type="supplementary-material"}), (2) the whole animal is amenable to pharmacological studies ([Figures 1](#fig1){ref-type="fig"}A and 1B), and (3) initial structure activity relationships can be determined to enable the design of biologically relevant probes for affinity purification ([Figure 2](#fig2){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}).

Despite the benefits of phenotypic screens in zebrafish, target identification remains a challenge in chemical biology ([@bib18]; [@bib37]; [@bib43]). Here, we use parallel approaches to enable identification of an important target of 5-nitrofurans. First, we used affinity chromatography to identify Aldh2 as a 5-nitrofuran binding partner and confirmed the dependence on the 5-NO~2~ functional group using an inactive furan probe ([Figure 2](#fig2){ref-type="fig"}). Second, we used computational modeling to predict that the ALDH2 inhibitor daidzin would be active in zebrafish ([Figure 3](#fig3){ref-type="fig"}A), and used two chemically distinct ALDH2 inhibitors (daidzin and DSF) to confirm the biological relevance of the 5-nitrofuran-Aldh2 interaction in vivo ([Figures 3](#fig3){ref-type="fig"}B and 3C). Third, we showed cross-species conservation of the drug-drug interactions in the evolutionarily distant budding yeast system ([Figures 4](#fig4){ref-type="fig"}A and 4B). Fourth, we used genetic mutants in yeast and gene knockdowns in zebrafish to validate a genetic dependence on ALDH activity for 5-nitrofuran activity in vivo ([Figures 4](#fig4){ref-type="fig"}C--E). Fifth, we showed that the 5-nitrofuran-ALDH2 interaction is maintained with human ALDH2 ([Figure 5](#fig5){ref-type="fig"}A). Finally, using a literature-precedent method, we showed that 5-nitrofurans are direct substrates of human ALDH2 ([Figures 5](#fig5){ref-type="fig"}B--5D).

We find that zebrafish melanocytes are sensitive to the 5-nitrofurans because unlike human melanocytes, zebrafish melanocytes use ALDH2 to elicit a melanocyte background adaptation response (camouflage; [Figure 3](#fig3){ref-type="fig"}D). While additional host enzymes, possibly including other ALDHs, may bioactivate 5-nitrofurans in patients, we speculate that, in line with our studies in zebrafish and yeast, daidzin may protect cells that specifically express ALDH2, such as the liver and dopaminergic neuronal cells ([Figure 6](#fig6){ref-type="fig"}A). Although 500 million individuals worldwide have an ALDH2-inactive variant ([@bib10]), it is unknown whether these genetic variants contribute to the variability of 5-nitrofuran-associated side effects; our chemical-genetic data in yeast and zebrafish ([Figure 4](#fig4){ref-type="fig"}) suggest that this hypothesis could be examined in the clinic. 5-Nitrofurans have also recently become anticancer agents, and nifurtimox is currently in clinical trials for relapsed/refractory pediatric neuroblastoma and medulloblastoma ([@bib33]). It is possible that 5-nitrofuran bioactivation by ALDH2 explains the sensitivity of these dopaminergic cancers to nifurtimox. We find that human melanoma cells are also sensitive to nitrofurans, that DNA damage occurs, and that this activity is dependent on the NO~2~ functional group present in NFN1 ([Figure S4](#app2){ref-type="sec"}). Taken together with the hypersensitivity of yeast DNA-damage mutants to NFN1, these results suggest that once activated, the cytotoxic effects of 5-nitrofurans arise through a similar DNA-damage-dependent mechanism across species, although it is unclear at this time whether NTR- and ALDH2-mediated activation of 5-nitrofurans leads to exactly the same toxic intermediates.

We argue that NFN1, but not the no-nitro NFN1.1, is a substrate for recombinant human ALDH2 in vitro ([Figure 5](#fig5){ref-type="fig"}). Analogous observations have been made in ALDH2 bioactivation of nitroglycerin ([@bib5]; [@bib39]), thereby raising the interesting question of how 5-nitrofurans are bioactivated by ALDH2. ALDH2 enzymes have reducing potential as well as dehydrogenase activity ([@bib6]; [@bib22]), and we envision that ALDH2 may reduce the nitro group of 5-nitrofurans, potentially generating nitroso-, hydroxylamine, and/or amine intermediates with concomitant oxidation of the enzyme. Interestingly, dithiothreitol (DTT) can react with 5-nitrofurans, leading to oxidation of DTT to the corresponding disulfide (L.Z. and N.W., unpublished data). As DTT contains two thiols in close proximity, in an analogous manner to the active site of ALDH2, we suggest that the reactions of 5-nitrofurans with ALDH2 and DTT may be linked by a common mechanism.

5-Nitrofurans are important therapeutic agents, yet many patients suffer from unacceptable drug-induced toxic side effects. One approach to solving this problem is to identify new antitrypanosome drug targets, such as the recently identified *N*-myristoyltransferase inhibitors ([@bib12]) that have been validated in mouse trypanosomiasis models. Based on our studies in model systems and in vitro, we propose a complementary approach that involves targeting and minimizing the toxic side effects of current therapies, thereby allowing more patients to benefit from approved treatment regimes that are already available ([Figure 6](#fig6){ref-type="fig"}A). If the 5-nitrofuran-ALDH2 interaction is conserved in patients, then combination therapy to treat 5-nitrofuran toxic side effects may be testable, because (1) ALDH2 is a targetable enzyme; (2) the ALDH2 inhibitors daidzin and DSF are both currently available at low cost and show activity in humans with limited toxicity; and (3) our analysis indicates that *T. brucei* and *T. cruzi* do not have a close ALDH2 homolog ([Figure S2](#app2){ref-type="sec"}), nor is *T. brucei* protected from nifurtimox by daidzin ([Figure 6](#fig6){ref-type="fig"}B). Our findings provide impetus for addressing the role of ALDH2 in 5-nitrofuran activation in the preclinical and clinical setting.

Significance {#sec4}
============

**Discovering how drugs work in vivo and identifying unintended drug targets is a fundamental challenge in chemical biology. Nifurtimox is one of only two drugs used to treat Chagas disease, caused by *Trypanosoma cruzi* infection, which is estimated to affect over 10 million people per year and kills between 15,000 and 50,000 annually. Like other 5-nitrofurans, nifurtimox is a prodrug that is activated by parasite-specific nitroreductases to a toxic form. Despite the absence of nitroreductases in humans, 5-nitrofurans cause significant clinical off-target toxic side effects that interfere with patients' ability to complete the treatment course. There has been no significant improvement in trypanosome disease treatment for 40 years, and there is currently no treatment strategy in patients to reduce the burden of these toxic side effects of existing drugs.**

**Here, we use model organism chemical genetics to explore the basis for this toxicity. We use the zebrafish model (1) to identify toxic effects of 5-nitrofuran compounds; (2) as a platform for structure-activity relationships and target identification; and (3) to show that the toxicity of 5-nitrofurans in zebrafish can be prevented by cotreatment with aldehyde dehydrogenase 2 (ALDH2) inhibitors. We then show that the ALDH2-5-nitrofuran interaction is conserved in yeast and with human ALDH2 and argue that 5-nitrofurans are a direct substrate of human ALDH2. We extend these findings to show that the 5-nitrofuran nifurtimox also has Aldh2-dependent activity in zebrafish, and that it is a direct substrate of human ALDH2. Thus, we show in model systems that drug treatments combining ALDH2 inhibitors with 5-nitrofurans block the 5-nitrofuran unintended biological activity, and we propose that similar treatments based on a readily available combination of inexpensive approved drugs may prevent some of the clinical side effects caused by 5-nitrofurans.**

Experimental Procedures {#sec5}
=======================

Zebrafish Small-Molecule Screens and Treatments {#sec5.1}
-----------------------------------------------

All zebrafish work was done in accordance with United Kingdom Home Office Animals (Scientific Procedures) Act (1986) and approved by the University of Edinburgh Ethical Review Committee. The chemical library was a collection of 1576 Maybridge compounds ([@bib13]). Two 4 hpf embryos were arrayed in 96 well plates containing 10 μM of compound in 1% DMSO in 300 μl of E3 embryo medium. Embryos were assessed and imaged for phenotypic changes at 28, 36, 48, and 56 hpf. For the screening of The Screen-Well Kinase Inhibitor Library (Enzo Life Sciences), five embryos (24 hpf) were placed into each well of a 24 well plate (Corning) containing 20 μM NFN1 (BTB05727, Maybridge Screening compounds) and 5, 10, or 20 μM of a corresponding compound (total volume 1 ml per well). For cotreatment experiments, five 36--48 hpf embryos were arrayed in 24 well plates in 600 μl to 1 ml of E3 embryo medium and pretreated with ALDH or PKC inhibitors (1--7 hr), and then treated with 0.5--5 μM NFN1 or 50 μM nifurtimox.

Affinity Purification and Coimmunoprecipitation with 5-Nitrofuran Beads {#sec5.2}
-----------------------------------------------------------------------

Lysate was generated from approximately 900 3 dpf zebrafish in 300 μl of RIPA buffer (2 M Tris pH 7.5, 5 M NaCl, 1% NP40, Na-deoxycholate, 10% SDS, 0.5 M NaF, 1 M β-glycosyl phosphate and protease-inhibitor cocktail tablet \[Roche\]), centrifuged at 4°C (25 min), transferred to a new tube, and kept on ice. Protein capture was performed using a pull-down biotinylated protein:protein interaction kit (Pierce) using the biotinylated chemical probe (5 μl 10 mg/ml DMSO solution), and bead complexes were washed with 0.1 M NaCl TBS buffer four times to reduce nonspecific binding. Beads were boiled in 3× Laemmli buffer with DTT for 5 min and run on 10% SDS-PAGE gel for electrophoresis. Captured proteins were visualized with a Silverquest silver-staining kit and/or Colloidal blue-staining kit (Invitrogen). The mass spectroscopy was analyzed in the University of Dundee FingerPrints Proteomics Facility. For western blotting, protein was detected using rabbit anti-zebrafish Aldh2 (1:1000) and goat anti-rabbit antibody (1.5:5000; Calbiochem).

In Vitro Binding Assay {#sec5.3}
----------------------

ALDH2 human recombinant protein (ProSpec) was added to 4 μl 10 mg/ml of chemical probe with 100 μl TBS buffer and incubated at room temperature for 1 hr. Streptavidin bead suspension (50 μl) was added to the mixture (room temperature; 1 hr), the supernatant was removed, and beads were washed with 4 × 0.1 M NaCl TBS buffer, boiled in 3× Laemmli buffer with DTT for 5 min, and run on 10% SDS-PAGE gel for electrophoresis. The bands were detected by silver staining (Invitrogen).

Molecular Modeling {#sec5.4}
------------------

Using methods analogous to those used previously ([@bib24]), the zebrafish Aldh2b homology model was generated using the Swiss model server using bovine ALDH2 (PDB code [2AG8](pdb:2AG8)). The daidzin structure was generated using the PRODRG server. The docking studies were performed using the program GOLD. All visualization and analysis was performed using Pymol.

Yeast Growth Assays {#sec5.5}
-------------------

Overnight *S. cerevisiae* BY4741 cultures in SC media were diluted (OD~600~ 0.025) and dispensed into 96 well Corning Costar assay plates. Quantitative growth curves were generated in Tecan Sunrise plate readers at 30°C 564 rpm with automated absorbance reads every 15 min. Growth-curve data were used to determine when control cultures reached late log phase, and OD values of the entire plate at that time point were used to calculate normalized growth values. Data were analyzed with custom R scripts to generate plots. For the deletion-strain growth curves, normalization was performed against control wells for each strain.

Trypanocidal Studies {#sec5.6}
--------------------

The trypanocidal activity of nifurtimox in the absence and presence of daidzin (100 μM) against *Trypanosoma brucei* bloodstream form (strain 427) were cultured at 37°C in HMI9 medium supplemented with 2.5 μg ml^−1^ G418, and viability was determined using the Alamar Blue test, as described previously ([@bib25]). The data were fitted using GraFit software to obtain ED~50~ ± SD and slope factors.

Supplemental Experimental Procedures {#sec5.7}
------------------------------------

The synthesis of all the NFNs and NFN-based affinity probes is described in the [Supplemental Information](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================

Document 1. Figures S1--S4, Table S1, and Supplemental Experimental ProceduresMovie S1. Time-Lapse Imaging of 5-Nitrofuran Treatment of Live Zebrafish, Related to Figure 1
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Supplemental Information includes four figures, one table, Supplemental Experimental Procedures, and one movie and can be found with this article online at [http://dx.doi.org/10.1016/j.chembiol.2012.05.017](10.1016/j.chembiol.2012.05.017).

![5-Nitrofurans Promote Melanocytotoxicity in Zebrafish\
(A and B) Examples of zebrafish embryos treated at 2 dpf for 48 hr with DMSO as a control, plus 5 μM NFN1 and 5 μM NFN1.1 (A) or 50 μM nifurtimox (B). Black melanocytes (red arrows) and melanocyte detritus (blue arrows) are indicated.\
(C) Chemical structures of the four 5-nitrofurans (NFN1--4 \[Maybridge compounds BTB05727, SEW00138, BTB13657, and BR00087\]) identified in a chemical screen for modulators of melanocyte development. The 5-NO~2~-furan functional group shared between the 5-nitrofurans, including nifurtimox, is indicated in red. The chemical structure of NFN1.1. is identical to that of NFN1 but lacks the 5-NO~2~ functional group required for activity (blue).\
See also [Figure S1](#app2){ref-type="sec"} and [Movie S1](#mmc2){ref-type="supplementary-material"}.](gr1){#fig1}

![5-Nitrofurans Bind Aldh2 in Zebrafish\
(A) Biotinylated probes linked to a 5-nitrofuran (Pr-NFN) and a control furan (Pr-FN). Biotin is labeled in blue and the 5-nitro or modification moiety in red.\
(B) Silver stain of protein bands identified using Pr-NFN probe, or streptavidin beads alone as a control (No Probe). The red box indicates the region of the gel that was isolated for mass spectrometry analysis (arrow) at 57 kD.\
(C) Western blot of zebrafish protein bound to the no-probe control, the furan (Pr-FN) control, or the 5-nitrofuran probe (Pr-NFN), and probed with zebrafish anti-Aldh2 antibodies. A band corresponding to 57 kDa is indicated (arrow). MW, molecular weight.\
See also [Figure S2](#app2){ref-type="sec"} and [Table S1](#app2){ref-type="sec"}.](gr2){#fig2}

![Aldh2 Is Responsible for 5-Nitrofuran Activity in Zebrafish\
(A) A predicted model of daidzin binding to zebrafish ALDH2b, based on key residues involved in the human ALDH2-daidzin (PDB [2vle](pdb:2vle)) protein-ligand interaction ([@bib21]). The equivalent residues in zebrafish Aldh2b are shown. Human ALDH2→Zebrafish Aldh2 2b (Phe-459→Phe-457; Phe-170→Phe-186; Trp-177→Trp-193; Val-120→Val-136; Phe-296→Phe-312; Phe-292→Ile-308; Asp-457→Asn-473; Cys-303→Cys-319).\
(B) Aldh2 and PKC inhibitors prevent 5-nitrofuran activity in zebrafish. Examples of zebrafish embryos treated at 2 dpf with 20 μM of the ALDH inhibitors daidzin or DSF for 1 hr, or with 20 μM of the PKC inhibitors PKC412 or Ro318220, and then treated with 5 μM NFN1 or 0.1% DMSO alone for 2 days. Experiments were repeated at least three times, with n \> 10 embryos per condition.\
(C) Examples of 2 dpf zebrafish embryos pretreated with DMSO, 30 μM of daidzin, or the PKC inhibitor GFX 109203X for 1 hr, and then treated with 50 μM nifurtimox for 7 hr. Punctate melanocytes are indicated. Experiments were repeated at least three times (n = 5--10 embryos per condition) and treatment-condition cohorts blind scored.\
(D) Daidzin alters background adaptation in zebrafish embryos. (Left) Images of fixed zebrafish embryos (5 dpf) treated with 0.1% DMSO or 10 μM daidzin, and shifted from a dark environment to a light environment (light), or vice versa (dark). The average percentage of melanin coverage (within the area indicated by the red dotted outline) for each treatment condition ± SD is indicated. (Right) Box plot of melanin coverage (y axis) for each embryo in different treatment conditions (x axis). Individual values taken from one of three experiments are shown as red circles. The box depicts the lower quartile and the upper quartile, with the median depicted by the intersecting line. Whiskers extend between the minimum and maximum of all the data. In DMSO-treated embryos, melanocytes are significantly contracted in the light and expanded in the dark (p \< 0.001, n = 20 for each condition; ANOVA, 95% confidence interval \[CI\] 11.081\[5.966, 16.195\]). Zebrafish treated with daidzin contract their melanin in response to light environment but do not significantly expand their melanin in response to dark environments (95% CI 0.563\[−4.552, 5.677\]). The experiment was repeated three separate times with embryos at 5 dpf (n = 5--20 embryos per condition) and once with embryos at 4 dpf (n = 10 embryos per condition).\
See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![Cross-Species Conservation of 5-Nitrofuran-ALDH2 Interaction in Yeast\
(A) Yeast cultures were treated with NFN1 (red) or NFN1.1 (blue). OD values were normalized against DMSO-treated controls. The mean of two experiments with three replicates is shown; error bars represent the SE.\
(B) Daidzin-NFN1 drug interaction was assessed by combination matrix assays in 96 well plates. Cultures were treated with NFN1 (red) or with daidzin in the absence (blue) or presence (black) of 50 μM NFN1. The average normalized growth of three experiments is shown; error bars represent the SE.\
(C) Normalized growth in the presence of NFN1 was determined for wild-type (blue) and the *Δald6* strain (red). Data points are the mean of four replicates; error bars represent the SE.\
(D) NFN1 dose response curves for Δ*ald2*Δ*ald3* (red) and the Δ*ald2*Δ*ald3Δald6* (black) strains, as well as wild-type control (blue), were generated and normalized against DMSO-treated controls. The average of three replicates is shown; error bars represent the SE.\
(E) Control (n = 24) or *aldh2b* splice-site morphants (n = 62) at 3 dpf without NFN1 treatment (left) or with 0.8 μM NFN1 treatment (right). Embryos were scored as class I (strong) or class II (mild) sensitivity to NFN1 (bar graph). *aldh2b* morphant embryos were less sensitive to NFN1 treatment compared to control morphants (p = 0.007; 95% CI \[0.139, 0.528\]; Fisher's exact test).\
See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}

![5-Nitrofurans Bind and Are Substrates for Human ALDH2 In Vitro\
(A) Binding of purified human ALDH2 by 5-nitrofuran probe (Pr-NFN), a furan control probe (Pr-FN), or streptavidin beads alone (No Probe). Arrow indicates ALDH2 protein, ALDH2 input lane (0.5 μg).\
(B) Schematic overview of chemical reaction used to monitor recombinant human ALDH2 activity and experimental design. In experiment C (red arrow), ALDH2 was incubated with 1% DMSO, NFN1, and NFN1.1 or Nifurtimox for 10 min., and then ALDH2 activity was assessed. In experiment D (red + blue arrows), ALDH2 was incubated with 1% DMSO, NFN1, or Nifurtimox for 10 min., incubated with 0.5 mM TCEP or buffer alone for a further 15 min., and then ALDH2 activity was assessed.\
(C) Bar graph of spectrophotometric analysis of the rate of production of NADH (monitored at 341 nm) by ALDH2 (expressed as a percentage of DMSO control treatment) with DMSO, NFN1, NFN1.1, and Nifurtimox.\
(D) Bar graph of spectrophotometric analysis of the rate of production of NADH by ALDH2 after combined treatment of DMSO, NFN1, and Nifurtimox with TCEP or buffer. Enzyme buffer = 50 mM sodium phosphate (pH 7.4). Error bars are SD; experiments were repeated in triplicate.](gr5){#fig5}

![ALDH2 in Trypanosomes\
(A) Schematic of a 5-nitrofuran-daidzin combination-treatment strategy. ALDH2 can cause 5-nitrofuran bioactivtion in ALDH2-expressing cells (e.g., zebrafish melanocytes), but not in trypanosomes because they lack ALDH2 (see also [Figure S2](#app2){ref-type="sec"}). We propose that cotreatment with an ALDH2 inhibitor such as daidzin could limit 5-nitrofuran toxicity without interfering with antitrypanosome activity.\
(B) Viability of *Trypanosoma brucei* (bloodstream form) at 37°C after 72 hr treatment with increasing concentrations of nifurtimox in the absence or presence of daidzin (100 μM). Experiments were conducted twice in replicates of four; a representative set of data from one experiment containing four replicates is shown. ED, effective dose.](gr6){#fig6}

###### 

Derivatives of 5-Nitrofurans and Their Activity in Zebrafish

  Compound   0.2 μM        0.4 μM        0.8 μM        1.6 μM
  ---------- ------------- ------------- ------------- ---------------------------------------
  NFN1       No activity   No activity   \+            +++
  NFN1.1     No activity   No activity   No activity   No activity
  NFN5       No activity   \+            ++            ++++
  NFN5.1     No activity   \+            ++            ++
  NFN5.2     No activity   \+            ++            ++++[a](#tblfn1){ref-type="table-fn"}

+Some melanocytes become dendritic, few are fragmented.

++Some punctate and fragmented melanocytes.

+++All melanocytes are punctate, many clearly fragmented, pigment remains in eye.

++++All melanocytes are fragmented, with almost complete loss of pigment in body and eye.

Additional nonspecific toxicity.

[^1]: These authors contributed equally to this work
